Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

argenx SE - American Depositary Shares (NQ:ARGX)

884.20 -9.32 (-1.04%)

Streaming Delayed Price Updated: 4:00 PM EDT, Jun 15, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	423,156
Open	892.19
Bid (Size)	860.00 (40)
Ask (Size)	1,000.00 (40)
Prev. Close	893.52
Today's Range	876.65 - 892.89
52wk Range	510.06 - 934.62
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

argenx Eyes More VYVGART Growth as Pipeline Catalysts Near ↗

June 12, 2026

Executives at argenex (NASDAQ:ARGX) told investors at a Goldman Sachs healthcare event that they continue to see meaningful growth opportunities for VYVGART across myasthenia gravis and chronic...

Via MarketBeat

argenx Touts VYVGART Growth, 50,000-Patient Goal at William Blair Conference ↗

June 05, 2026

argenx (NASDAQ:ARGX) Chief Financial Officer Karl Gubitz told investors at the 46th Annual William Blair Growth Stock Conference that the biotechnology company remains focused on revenue growth,...

Via MarketBeat

Performance

YTD	+5.3%	+5.3%
1 Month	+13.9%	+13.9%
3 Month	+25.7%	+25.7%
6 Month	+3.9%	+3.9%
1 Year	+60.4%	+60.4%

More News

argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren’s Disease at EULAR 2026

June 03, 2026

From argenx SE

Via GlobeNewswire

Why This Fund Made a $189 Million Bet on Erasca as Shares Skyrocket 800% ↗

May 29, 2026

Via The Motley Fool

Tango Therapeutics Stock Is Up 840%, and This Fund Just Disclosed Buying $164 Million More ↗

May 29, 2026

Via The Motley Fool

argenx to Host Myositis R&D Webinar on June 23, 2026

May 28, 2026

From argenx SE

Via GlobeNewswire

argenx to Present at Upcoming Investor Conferences

May 27, 2026

From argenx SE

Via GlobeNewswire

Patient Square Makes a Big Bet on Nektar Pharmaceuticals (NKTR) Purchasing 210,000 Shares ↗

May 16, 2026

Via The Motley Fool

2 Ways to Play the Big Pharma Patent Cliff ↗

May 15, 2026

Via MarketBeat

argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG

May 08, 2026

From argenx SE

Via GlobeNewswire

argenx Reports First Quarter 2026 Financial Results and Provides Business Update

May 07, 2026

From argenx SE

Via GlobeNewswire

argenx to Present at BofA Securities 2026 Health Care Conference

May 06, 2026

From argenx SE

Via GlobeNewswire

argenx Announces Results of Annual General Meeting and Board of Directors’ Appointment of Karen Massey as Chief Executive Officer

May 06, 2026

From argenx SE

Via GlobeNewswire

argenx to Report First Quarter 2026 Financial Results and Business Update on May 7, 2026

April 30, 2026

From argenx SE

Via GlobeNewswire

argenx Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDP

April 18, 2026

From argenx SE

Via GlobeNewswire

This New $193 Million Bet Targets a Biotech With $689 Million in Revenue and a Potential Turnaround Story ↗

March 21, 2026

Via The Motley Fool

This $116 Million Buy Joins a 360% Stock Run and Seemingly Signals Conviction in a Key Drug Launch ↗

March 21, 2026

Via The Motley Fool

argenx announces Annual General Meeting of Shareholders on May 6, 2026

March 20, 2026

From argenx SE

Via GlobeNewswire

This Specialized Heart Monitor Maker Just Caught the Eye of a Major Healthcare Fund ↗

March 20, 2026

Via The Motley Fool

Complementing the Future: A Deep Dive into Dianthus Therapeutics (DNTH) After Its Phase 3 Breakthrough

March 12, 2026

Via Finterra

DNTH Stock Soars After Early ‘Go’ Decision For Drug In Autoimmune Disorder Program, Boosting Wall Street Optimism For Potential Launch ↗

March 09, 2026

Via Stocktwits

argenx to Present New Data at 2026 AAN Annual Meeting that Continue to Transform Patient Outcomes in MG and CIDP and Build Upon Strength of Pipeline

March 06, 2026

From argenx SE

Via GlobeNewswire

Argenx (ARGX) 2026 Feature: The Anatomy of a Biotech Powerhouse Transitioning to Profitability

February 26, 2026

Via Finterra

argenx Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update

February 26, 2026

From argenx SE

Via GlobeNewswire

argenx Announces Positive Topline Results from Phase 3 ADAPT OCULUS Trial of VYVGART in Ocular Myasthenia Gravis

February 26, 2026

From argenx SE

Via GlobeNewswire

Frequently Asked Questions

Is argenx SE - American Depositary Shares publicly traded?

Yes, argenx SE - American Depositary Shares is publicly traded.

What exchange does argenx SE - American Depositary Shares trade on?

argenx SE - American Depositary Shares trades on the Nasdaq Stock Market

What is the ticker symbol for argenx SE - American Depositary Shares?

The ticker symbol for argenx SE - American Depositary Shares is ARGX on the Nasdaq Stock Market

What is the current price of argenx SE - American Depositary Shares?

The current price of argenx SE - American Depositary Shares is 884.20

When was argenx SE - American Depositary Shares last traded?

The last trade of argenx SE - American Depositary Shares was at 06/15/26 04:00 PM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.